Immune priming therapy shows promise in tough prostate cancer

NCT ID NCT06056791

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 34 times

Summary

This early-phase study tested a new cell therapy called INKmune in 12 men with advanced prostate cancer that no longer responds to hormone therapy. The treatment aims to boost the body's natural killer cells to fight the cancer. Researchers looked for the safest and most effective dose by monitoring immune response, PSA levels, and tumor changes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Carl & Edyth Lindner Center for Research and Education at The Christ Hospital and The Christ Hospital Cancer Center

    Cincinnati, Ohio, 45219, United States

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada, 89169, United States

  • NEXT Virginia

    Fairfax, Virginia, 22031, United States

  • Renovatio Clinical

    El Paso, Texas, 79915, United States

  • Renovatio Clinical

    The Woodlands, Texas, 77380, United States

  • University of California, Los Angeles

    Los Angeles, California, 90095, United States

  • VA Greater Los Angeles Healthcare System

    Los Angeles, California, 90073, United States

  • VA Puget Sound Health Care System

    Seattle, Washington, 98108, United States

Conditions

Explore the condition pages connected to this study.